Why Revance Therapeutics Is Soaring Today

In response to the company's strong results from two pivotal phase 3 trials, shares of Revance Therapeutics (NASDAQ: RVNC), a clinical-stage biotech focused on aesthetics, rose 36% as of 11:10 a.m. EST on Tuesday.

Revance announced top-line results from its two Sakura phase 3 trials. These studies were designed to evaluate a compound called RT002 as a treatment for glabellar lines, which are the short vertical lines found between the eyebrows.

Both phase 3 trials met their primary endpoint, which was defined as a statistically significant improvement in reducing the severity of glabellar lines when compared to a placebo.

Source: Fool.com